Annual report pursuant to Section 13 and 15(d)

BALANCE SHEETS

v3.19.1
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 9,295 $ 7,522
Restricted cash 361 361
Receivables 1,737 65
Inventory 1,262 0
Contract assets 99 0
Prepaid expenses and other current assets 547 362
Total current assets 13,301 8,310
Property and equipment, net 794 595
Total Assets 14,095 8,905
Current liabilities:    
Accounts payable 1,526 821
Accrued clinical trials expenses 620 289
Other accrued liabilities 466 354
Deferred revenue 313 0
Current portion of long-term debt, net of debt discount of $123,000 527 3,000
Total current liabilities 3,452 4,464
Long-term debt, net of debt discount of $543,000 and $497,000 3,787 3,584
Derivative liability 25 0
Total Liabilities 7,264 8,048
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2018 and 2017. 0 0
Common stock, at amounts paid-in, $0.001 par value per share; 125,000,000 shares authorized, 13,010,292 and 3,533,958 shares issued and outstanding at December 31, 2018 and 2017, respectively. 13 4
Additional paid-in capital 339,397 324,124
Accumulated deficit (332,579) (323,271)
Total stockholders' equity 6,831 857
Total Liabilities and Stockholders' Equity $ 14,095 $ 8,905